Details of the Drug

General Information of Drug (ID: DM1XHYJ)

Drug Name
Etidronic acid
Synonyms
EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL
Indication
Disease Entry ICD 11 Status REF
Paget's disease FB85 Approved [1], [2]
Therapeutic Class
Bone Density Conservation Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 206.03
Topological Polar Surface Area (xlogp) -3.7
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 1-10% [4]
Clearance
The renal clearance of drug is 0.09 L/h/kg [4]
Elimination
50% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 6 hours [4]
Metabolism
The drug is not metabolised [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 97.07349 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 0.3-1.3 L/kg [4]
Chemical Identifiers
Formula
C2H8O7P2
IUPAC Name
(1-hydroxy-1-phosphonoethyl)phosphonic acid
Canonical SMILES
CC(O)(P(=O)(O)O)P(=O)(O)O
InChI
InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
InChIKey
DBVJJBKOTRCVKF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3305
ChEBI ID
CHEBI:4907
CAS Number
2809-21-4
DrugBank ID
DB01077
TTD ID
D00NNC
ACDINA ID
D00256

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein-tyrosine phosphatase sigma (R-PTP-sigma) TTCWXFA PTPRS_HUMAN Inhibitor [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Paget's disease
ICD Disease Classification FB85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Protein-tyrosine phosphatase sigma (R-PTP-sigma) DTT PTPRS 1.17E-01 0.21 0.65
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Etidronic acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Etidronic acid caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [8]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Etidronic acid and Inotersen. Amyloidosis [5D00] [8]
Kanamycin DM2DMPO Moderate Increased risk of hypocalcemia by the combination of Etidronic acid and Kanamycin. Bacterial infection [1A00-1C4Z] [9]
Streptomycin DME1LQN Moderate Increased risk of hypocalcemia by the combination of Etidronic acid and Streptomycin. Bacterial infection [1A00-1C4Z] [9]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Etidronic acid and Iodipamide. Cholelithiasis [DC11] [10]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [9]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Etidronic acid and Etelcalcetide. Hyper-parathyroidism [5A51] [8]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [9]
Iron DMAP8MV Moderate Decreased absorption of Etidronic acid due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [11]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [9]
Exjade DMHPRWG Major Increased risk of GI mucosal injury/bleeding risk by the combination of Etidronic acid and Exjade. Mineral absorption/transport disorder [5C64] [12]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Etidronic acid due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [13]
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Gallium nitrate. Mineral excesses [5B91] [9]
Choline salicylate DM8P137 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etidronic acid and Choline salicylate. Postoperative inflammation [1A00-CA43] [14]
Temsirolimus DMS104F Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Temsirolimus. Renal cell carcinoma [2C90] [9]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Colistimethate. Respiratory infection [CA07-CA4Z] [9]
Salsalate DM13P4C Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Salsalate. Rheumatoid arthritis [FA20] [14]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [9]
Lenvatinib DMB1IU4 Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Lenvatinib. Thyroid cancer [2D10] [9]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Etidronic acid and Olsalazine. Ulcerative colitis [DD71] [9]
Plazomicin DMKMBES Moderate Increased risk of hypocalcemia by the combination of Etidronic acid and Plazomicin. Urinary tract infection [GC08] [9]
⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Etidronic acid 200 mg tablet 200 mg Oral Tablet Oral
Etidronic acid 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7184).
2 Drug information of Didronel, 2008. eduDrugs.
3 BDDCS applied to over 900 drugs
4 Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74. doi: 10.2165/00002512-199405060-00006.
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
10 Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
11 Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
12 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
13 Canadian Pharmacists Association.
14 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.